Skip to content

Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy - Post Assessment Survey

Thank you for watching 'Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy'. We’d like to ask a few short questions to gauge the impact of this activity.

If you wish to watch again or share with colleagues, you can watch, here.

This Independent Medical Education roundtable is supported by an unrestricted educational grant from AstraZeneca.
1.Having taken part in this activity, do you think it less likely you’d adjust or discontinue RAASi therapy in your patients due to hyperkalaemia?
2.Do you think the down-titration or discontinuation of RAASi due to hyperkalaemia is now an avoidable problem in patients with heart failure or CKD?
3.Having taken part in this activity, are you now more familiar with recent real-world data and peer experience supporting the use of potassium binders to enable optimised RAASi therapy by managing hyperkalaemia?
4.Do you intend to prescribe or recommend a potassium binder for patients to be able to continue RAASi therapy, now or in the future?